Holen Sie sich die Stockscreener-App
10.99
8.26%
0.82
Handel nachbörslich:
10.99
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $14 From $13, Maintains Outperform Rating - marketscreener.com
BCRXBiocryst Pharmaceuticals Inc Volatility & Greeks - Finviz
BioCryst lures 9 new hires with stock awards tied to $9.65 shares - Stock Titan
How Shutting Its Discovery Center To Pursue External Innovation At BioCryst (BCRX) Has Changed Its Investment Story - Sahm
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $16 to $32 - Moomoo
Rx Rundown: Zymeworks, Viridian Therapeutics, BioCryst and more - Medical Marketing and Media
BioCryst Pharmaceuticals Inc (BCRX) Stock Up 4.6% and Still Unde - GuruFocus
How (BCRX) Movements Inform Risk Allocation Models - Stock Traders Daily
BCRX Maintained by Cantor Fitzgerald -- Price Target Raised to $29 - GuruFocus
BioCryst to Close Birmingham Research Facility by End of 2026 - WBMA
BioCryst Pharmaceuticals (BCRX) Surges 4.8% as Bullish Volume Lifts Stock Toward Key ResistanceExtension Target - dars.gov.et
BCRX Maintained by HC Wainwright & Co. -- Price Target Stays at $32 - GuruFocus
BioCryst Pharmaceuticals Price Target Maintained With a $32.00/Share by HC Wainwright & Co. - Moomoo
BioCryst winds down internal discovery as it pivots to external innovation - The Pharma Letter
Jefferies raises BioCryst stock price target on R&D shift By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
BioCryst Pharmaceuticals (BCRX) Shifts Focus to External Innovat - GuruFocus
Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
BioCryst (BCRX) to Halt Internal Research Programs in Strategic Shift - GuruFocus
BioCryst Refocuses on External Innovation, Winds Down Internal R&D and Closes Birmingham Facility to Accelerate Rare Disease Pipeline Growth – Minichart - Minichart
BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs - marketscreener.com
BioCryst to close Alabama research facility, cut costs By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2000 Value Benchmark - marketscreener.com
BioCryst to close Alabama research facility, cut costs - Investing.com
BioCryst (NASDAQ: BCRX) lowers 2026 expenses and closes Birmingham R&D hub - Stock Titan
BioCryst shuts Birmingham lab, cuts 2026 spending outlook - Stock Titan
BCRX Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX - TradingView
Price to earnings forward of BioCryst Pharmaceuticals, Inc. – BX:BO1 - TradingView
Enterprise value to revenue forward of BioCryst Pharmaceuticals, Inc. – BX:BO1 - TradingView
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2500 Value Benchmark - marketscreener.com
Price to sales forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX - TradingView
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Price to sales forward of BioCryst Pharmaceuticals, Inc. – TRADEGATE:BO1 - TradingView
Enterprise value to revenue forward of BioCryst Pharmaceuticals, Inc. – TRADEGATE:BO1 - TradingView
Price to book forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX - TradingView
Enterprise value to EBITDA forward of BioCryst Pharmaceuticals, Inc. – TRADEGATE:BO1 - TradingView
Enterprise value to EBIT forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX - TradingView
BioCryst Pharmaceuticals, Inc. Actuals & Estimates (DUS:BO1) - TradingView
Fierce Biotech Layoff Tracker 2026: BioCryst ends internal programs; Biogen sheds Apellis R&D roles - Fierce Biotech
BioCryst Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:BCRX) - TradingView
BioCryst Pharmaceuticals, Inc. Actuals & Estimates (SWB:BO1) - TradingView
BCRX Stock Set For Best Week In Over 3 Months – Retail Shifts Focus To This Crucial Breakout Level - Yahoo Finance
Biocryst Pharmaceuticals stock hits 52-week high at $10.32 By Investing.com - Investing.com Australia
Biocryst Pharmaceuticals stock hits 52-week high at $10.32 - Investing.com
BioCryst Pharmaceuticals options trading jumps to 13,522 - Investing.com
BioCryst (BCRX) Is Up 11.7% After New HAE Data Spotlight ORLADEYO And Navenibart Potential - Sahm
BioCryst Pharmaceuticals options trading jumps to 13,522 By Investing.com - Investing.com Australia
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
BioCryst Pharmaceuticals Inc (BCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Trading Systems Reacting to (BCRX) Volatility - Stock Traders Daily
BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Chart - ChartMill
BioCryst Pharmaceuticals Inc (BCRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioCryst Pharmaceuticals Inc (BCRX) Institutional Confidence - TradingKey
BioCryst Pharmaceuticals Inc (BCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioCryst Pharmaceuticals Inc (BCRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
0.15%
1.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):